{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:29:52Z","timestamp":1788532192685,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08430-5","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:08:12Z","timestamp":1781867292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Hu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duonan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochuan","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9485-8686","authenticated-orcid":false,"given":"Jingying","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"2","key":"8430_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers (Basel). 2020;12(2):407. https:\/\/doi.org\/10.3390\/cancers12020407.","journal-title":"Cancers (Basel)"},{"issue":"19","key":"8430_CR2","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1182\/blood.2020008734","volume":"139","author":"E Kastritis","year":"2022","unstructured":"Kastritis E, Terpos E, Dimopoulos MA. How I treat relapsed multiple myeloma. Blood. 2022;139(19):2904\u201317. https:\/\/doi.org\/10.1182\/blood.2020008734.","journal-title":"Blood"},{"issue":"2","key":"8430_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.bbcan.2014.08.001","volume":"1846","author":"M Binsfeld","year":"2014","unstructured":"Binsfeld M, Fostier K, Muller J, Baron F, Schots R, Beguin Y, et al. Cellular immunotherapy in multiple myeloma: lessons from preclinical models. Biochim et Biophys Acta (BBA) - Rev Cancer. 2014;1846(2):392\u2013404. https:\/\/doi.org\/10.1016\/j.bbcan.2014.08.001.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"key":"8430_CR4","doi-asserted-by":"publisher","unstructured":"Tamura H, Ishibashi M, Sunakawa M, K. Inokuchi, immunotherapy for multiple myeloma. Cancers (Basel). 2019;11(12):2009. https:\/\/doi.org\/10.3390\/cancers11122009.","DOI":"10.3390\/cancers11122009"},{"issue":"7","key":"8430_CR5","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.7150\/jca.29993","volume":"10","author":"L Li","year":"2019","unstructured":"Li L, Wang L. Multiple myeloma: what Do we Do about immunodeficiency? J Cancer. 2019;10(7):1675\u201384. https:\/\/doi.org\/10.7150\/jca.29993.","journal-title":"J Cancer"},{"issue":"2","key":"8430_CR6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms23020904","volume":"23","author":"E Verheye","year":"2022","unstructured":"Verheye E, Melgar JB, Deschoemaeker S, Raes G, Maes A, Bruyne ED, et al. Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions. IJMS. 2022;23(2):904. https:\/\/doi.org\/10.3390\/ijms23020904.","journal-title":"IJMS"},{"key":"8430_CR7","doi-asserted-by":"publisher","first-page":"1027385","DOI":"10.3389\/fimmu.2022.1027385","volume":"13","author":"LS Boussi","year":"2022","unstructured":"Boussi LS, Avigan ZM, Rosenblatt J. Immunotherapy for the treatment of multiple myeloma. Front Immunol. 2022;13:1027385. https:\/\/doi.org\/10.3389\/fimmu.2022.1027385.","journal-title":"Front Immunol"},{"key":"8430_CR8","doi-asserted-by":"publisher","first-page":"1076096","DOI":"10.3389\/fphar.2022.1076096","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, Dai J, Xia J, Ye Z, Huang X, Cao W, et al. Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients. Front Pharmacol. 2022;13:1076096. https:\/\/doi.org\/10.3389\/fphar.2022.1076096.","journal-title":"Front Pharmacol"},{"key":"8430_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3389\/fphar.2019.01152","volume":"10","author":"O Markov","year":"2019","unstructured":"Markov O, Oshchepkova A, Mironova N. Immunotherapy based on Dendritic cell-Targeted\/-derived extracellular vesicles\u2014A novel strategy for enhancement of the anti-tumor immune response. Front Pharmacol. 2019;10:1152. https:\/\/doi.org\/10.3389\/fphar.2019.01152.","journal-title":"Front Pharmacol"},{"issue":"7","key":"8430_CR10","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3390\/cancers13071635","volume":"13","author":"X Wang","year":"2021","unstructured":"Wang X, He L, Huang X, Zhang S, Cao W, Che F, et al. Recent progress of exosomes in multiple myeloma: pathogenesis, diagnosis, prognosis and therapeutic strategies. Cancers (Basel). 2021;13(7):1635. https:\/\/doi.org\/10.3390\/cancers13071635.","journal-title":"Cancers (Basel)"},{"key":"8430_CR11","doi-asserted-by":"publisher","first-page":"155097","DOI":"10.1016\/j.prp.2024.155097","volume":"254","author":"G Tuluwengjiang","year":"2024","unstructured":"Tuluwengjiang G, Rasulova I, Ahmed S, Kiasari BA, S\u00e2rbu I, Ciongradi CI, et al. RETRACTED: dendritic cell-derived exosomes (dex): underlying the role of exosomes derived from diverse DC subtypes in cancer pathogenesis. Pathol - Res Pract. 2024;254:155097. https:\/\/doi.org\/10.1016\/j.prp.2024.155097.","journal-title":"Pathol - Res Pract"},{"issue":"1","key":"8430_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-020-01278-3","volume":"19","author":"Z Xu","year":"2020","unstructured":"Xu Z, Zeng S, Gong Z, Yan Y. Exosome-based immunotherapy: a promising approach for cancer treatment. Mol Cancer. 2020;19(1):160. https:\/\/doi.org\/10.1186\/s12943-020-01278-3.","journal-title":"Mol Cancer"},{"issue":"4","key":"8430_CR13","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1172\/jci81137","volume":"126","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Andr\u00e9 F, Amigorena S, Soria JC, Eggermont A, Kroemer G, et al. Dendritic cell\u2013derived exosomes for cancer therapy. J Clin Investigation. 2016;126(4):1224\u201332. https:\/\/doi.org\/10.1172\/jci81137.","journal-title":"J Clin Investigation"},{"key":"8430_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3389\/fimmu.2014.00518","volume":"5","author":"B Zhang","year":"2014","unstructured":"Zhang B, Yin Y, Lai RC, Lim SK. Immunotherapeutic potential of extracellular vesicles. Front Immunol. 2014;5:518. https:\/\/doi.org\/10.3389\/fimmu.2014.00518.","journal-title":"Front Immunol"},{"issue":"24","key":"8430_CR15","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","volume":"132","author":"L Garderet","year":"2018","unstructured":"Garderet L, Kuhnowski F, Berge B, Roussel M, Escoffre-Barbe M, Lafon I, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018;132(24):2555\u201363. https:\/\/doi.org\/10.1182\/blood-2018-07-863829.","journal-title":"Blood"},{"issue":"1","key":"8430_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22\u201332. https:\/\/doi.org\/10.1038\/leu.2009.236.","journal-title":"Leukemia"},{"key":"8430_CR17","doi-asserted-by":"publisher","unstructured":"Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013;3(9):e143. https:\/\/doi.org\/10.1038\/bcj.2013.38.","DOI":"10.1038\/bcj.2013.38"},{"issue":"3","key":"8430_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1615\/critrevimmunol.v25.i3.30","volume":"25","author":"J Ta\u00efeb","year":"2005","unstructured":"Ta\u00efeb J, Chaput N, Zitvogel L. Dendritic cell-derived exosomes as cell-free peptide-based vaccines. Crit Rev Immunol. 2005;25(3):215\u201323. https:\/\/doi.org\/10.1615\/critrevimmunol.v25.i3.30.","journal-title":"Crit Rev Immunol"},{"issue":"8","key":"8430_CR19","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/pharmaceutics15082070","volume":"15","author":"S Luo","year":"2023","unstructured":"Luo S, Chen J, Xu F, Chen H, Li Y, Li W. Dendritic cell-derived exosomes in cancer immunotherapy. Pharmaceutics. 2023;15(8):2070. https:\/\/doi.org\/10.3390\/pharmaceutics15082070.","journal-title":"Pharmaceutics"},{"issue":"14","key":"8430_CR20","doi-asserted-by":"publisher","first-page":"11306","DOI":"10.3390\/ijms241411306","volume":"24","author":"R Elsayed","year":"2023","unstructured":"Elsayed R, Elashiry M, Tran C, Yang T, Carroll A, Liu Y, et al. Engineered human Dendritic cell exosomes as effective delivery System for immune modulation. IJMS. 2023;24(14):11306. https:\/\/doi.org\/10.3390\/ijms241411306.","journal-title":"IJMS"},{"key":"8430_CR21","doi-asserted-by":"publisher","unstructured":"Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology. 2016;5(4):e1071008. https:\/\/doi.org\/10.1080\/2162402x.2015.1071008.","DOI":"10.1080\/2162402x.2015.1071008"},{"issue":"4","key":"8430_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/mt.2008.1","volume":"16","author":"S Dai","year":"2008","unstructured":"Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther. 2008;16(4):782\u201390. https:\/\/doi.org\/10.1038\/mt.2008.1.","journal-title":"Mol Ther"},{"issue":"4","key":"8430_CR23","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.4049\/jimmunol.172.4.2126","volume":"172","author":"F Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 F, Chaput N, Schartz N-S-CR20EC, Flament C, Aubert N, Bernard J, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I\/peptide complexes to dendritic cells. J Immunol. 2004;172(4):2126\u201336. https:\/\/doi.org\/10.4049\/jimmunol.172.4.2126.","journal-title":"J Immunol"},{"issue":"15","key":"8430_CR24","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.3390\/cancers13153667","volume":"13","author":"Y Yao","year":"2021","unstructured":"Yao Y, Fu C, Zhou L, Mi QS, Jiang A. DC-Derived exosomes for cancer immunotherapy. Cancers (Basel). 2021;13(15):3667. https:\/\/doi.org\/10.3390\/cancers13153667.","journal-title":"Cancers (Basel)"},{"key":"8430_CR25","doi-asserted-by":"publisher","unstructured":"Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012;119(3):756\u2013766. https:\/\/doi.org\/10.1182\/blood-2011-02-338004.","DOI":"10.1182\/blood-2011-02-338004"},{"issue":"1","key":"8430_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12964-023-01102-7","volume":"21","author":"FNA Jahromi","year":"2023","unstructured":"Jahromi FNA, Dowran R, Jafari R. Recent advances in the roles of exosomal microRNAs (exomiRs) in hematologic neoplasms: pathogenesis, diagnosis, and treatment. Cell Commun Signal. 2023;21(1):88. https:\/\/doi.org\/10.1186\/s12964-023-01102-7.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"8430_CR27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/cells9041044","volume":"9","author":"M Groot","year":"2020","unstructured":"Groot M, Lee H. Sorting mechanisms for MicroRNAs into extracellular vesicles and their associated diseases. Cells. 2020;9(4):1044. https:\/\/doi.org\/10.3390\/cells9041044.","journal-title":"Cells"},{"issue":"1","key":"8430_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41392-023-01704-0","volume":"9","author":"F Tan","year":"2024","unstructured":"Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes, signal Transduct target Ther. Signal Transduct Targeted Ther. 2024;9(1):17. https:\/\/doi.org\/10.1038\/s41392-023-01704-0.","journal-title":"Signal Transduct Targeted Ther"},{"key":"8430_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cellimm.2025.104931","volume":"409-410","author":"U Basak","year":"2025","unstructured":"Basak U, Chakraborty S, Mukherjee S, Pati S, Khan P, Ghosh S, et al. Breast cancer stem cells convert anti-tumor CD4+ T cells to pro-tumor T regulatory cells: potential role of exosomal FOXP3. Cellular Immunol. 2025) 104931. 409-410:409\u201310. https:\/\/doi.org\/10.1016\/j.cellimm.2025.104931.","journal-title":"Cellular Immunol"},{"key":"8430_CR30","doi-asserted-by":"publisher","first-page":"155255","DOI":"10.1016\/j.phymed.2023.155255","volume":"124","author":"WW Cai","year":"2024","unstructured":"Cai WW, Gao Y, Cheng JW, Yu Y, Zong SY, Li YH, et al. Berberine modulates the immunometabolism and differentiation of CD4+ T cells alleviating experimental arthritis by suppression of M1-exo-miR155. Phytomedicine. 2024;124:155255. https:\/\/doi.org\/10.1016\/j.phymed.2023.155255.","journal-title":"Phytomedicine"},{"issue":"1","key":"8430_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13577-024-01162-y","volume":"38","author":"Y Rong","year":"2024","unstructured":"Rong Y, Lu W, Huang X, Ji D, Tang D, Huang R, et al. Exosomal miR-146a-5p derived from bone marrow mesenchymal stromal cells regulate Th1\/Th2 balance and alleviates immune thrombocytopenia in pregnancy. Hum Cell. 2024;38(1):31. https:\/\/doi.org\/10.1007\/s13577-024-01162-y.","journal-title":"Hum Cell"},{"key":"8430_CR32","doi-asserted-by":"publisher","unstructured":"Mirza S, Penny C, Jain NK, RM. Rawal, curcumin mediated dendritic cell maturation by modulating cancer associated fibroblasts-derived exosomal miRNA-146a. J Cancer Res Ther. 2023;19(Suppl 2):S649\u2013s657. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1286_22.","DOI":"10.4103\/jcrt.jcrt_1286_22"},{"issue":"1","key":"8430_CR33","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/s13046-018-0965-2","volume":"37","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Ren H, Dai B, Li J, Shang L, Huang J, et al. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J Exp Clin Cancer Res. 2018;37(1):324. https:\/\/doi.org\/10.1186\/s13046-018-0965-2.","journal-title":"J Exp Clin Cancer Res"},{"key":"8430_CR34","doi-asserted-by":"publisher","first-page":"133594","DOI":"10.1016\/j.ijbiomac.2024.133594","volume":"275","author":"M Lv","year":"2024","unstructured":"Lv M, Li X, Zheng C, Tian W, Yang H, Yin Z, et al. Exosomal miR-130b-3p suppresses metastasis of non-small cell lung cancer cells by targeting DEPDC1 via TGF-\u03b2 signaling pathway. Int J Biol Macromolecules. 2024;275:133594. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.133594.","journal-title":"Int J Biol Macromolecules"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08430-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08430-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08430-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:11:25Z","timestamp":1788531085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08430-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8430"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08430-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures involving human participants in this study were conducted in accordance with the Declaration of Helsinki and the ethical standards of the respective institutions\/nations. This study was approved by the Ethics Committee of Sichuan Provincial People\u2019s Hospital. All the donors signed informed consent forms.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1137"}}